Literature DB >> 1672291

Genetic mapping of new RFLPs at Xq27-q28.

G K Suthers1, I Oberlé, J Nancarrow, J C Mulley, V J Hyland, P J Wilson, J McCure, C P Morris, J J Hopwood, J L Mandel.   

Abstract

The development of the human gene map in the region of the fragile X mutation (FRAXA) at Xq27 has been hampered by a lack of closely linked polymorphic loci. The polymorphic loci DXS369 (detected by probe RN1), DXS296 (VK21A, VK21C), and DXS304 (U6.2) have recently been mapped to within 5 cM of FRAXA. The order of loci near FRAXA has been defined on the basis of physical mapping studies as cen-F9-DXS105-DXS98-DXS369-DXS297-FRAXA-++ +DXS296-IDS-DXS304-DXS52-qter. The probe VK23B detected HindIII and XmnI restriction fragment length polymorphisms (RFLPs) at DXS297 with heterozygote frequencies of 0.34 and 0.49, respectively. An IDS cDNA probe, pc2S15, detected StuI and TaqI RFLPs at IDS with heterozygote frequencies of 0.50 and 0.08, respectively. Multipoint linkage analysis of these polymorphic loci in normal pedigrees indicated that the locus order was F9-(DXS105, DXS98)-(DXS369, DXS297)-(DXS293,IDS)-DXS304-DXS52. The recombination fractions between adjacent loci were F9-(0.058)-DXS105-(0.039)-DXS98-(0.123)-DXS369-(0.00)- DXS297-(0.057)-DXS296- (0.00)-IDS-(0.012)-DXS304-(0.120)-DXS52. This genetic map will provide the basis for further linkage studies of both the fragile X syndrome and other disorders mapped to Xq27-q28.

Entities:  

Mesh:

Year:  1991        PMID: 1672291     DOI: 10.1016/0888-7543(91)90218-4

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  20 in total

1.  Gene diagnosis and carrier detection in Hunter syndrome by the iduronate-2-sulphatase cDNA probe.

Authors:  A Gal; M Beck; A C Sewell; C P Morris; E Schwinger; J J Hopwood
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Linkage to Xq28 in a family with nonspecific X-linked mental retardation.

Authors:  A M Nordström; M Penttinen; H von Koskull
Journal:  Hum Genet       Date:  1992-11       Impact factor: 4.132

3.  Fragile X syndrome: diagnosis using highly polymorphic microsatellite markers.

Authors:  R I Richards; Y Shen; K Holman; H Kozman; V J Hyland; J C Mulley; G R Sutherland
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

4.  Characterization of a deletion at Xq27-q28 associated with unbalanced inactivation of the nonmutant X chromosome.

Authors:  J T Clarke; P J Wilson; C P Morris; J J Hopwood; R I Richards; G R Sutherland; P N Ray
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

5.  Estimation of an approximate confidence interval for FRAXA location by using linkage data from many pedigrees.

Authors:  G Suthers
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

6.  Fragile-X syndrome: unique genetics of the heritable unstable element.

Authors:  S Yu; J Mulley; D Loesch; G Turner; A Donnelly; A Gedeon; D Hillen; E Kremer; M Lynch; M Pritchard
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

7.  Molecular analysis in patients with mucopolysaccharidosis type II suggests that DXS466 maps within the Hunter gene.

Authors:  C Steglich; S Bunge; T Hulsebos; M Beck; N J Brandt; E Schwinger; J J Hopwood; A Gal
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

8.  Genetic heterogeneity in X-linked hydrocephalus: linkage to markers within Xq27.3.

Authors:  L Strain; C M Gosden; D J Brock; D T Bonthron
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

9.  X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies.

Authors:  D G Bichet; G N Hendy; M Lonergan; M F Arthus; S Ligier; Z Pausova; R Kluge; H Zingg; P Saenger; E Oppenheimer
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

10.  Structural gene aberrations in mucopolysaccharidosis II (Hunter).

Authors:  M Wehnert; J J Hopwood; W Schröder; F H Herrmann
Journal:  Hum Genet       Date:  1992-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.